N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)]thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 5, 2007, Pages 278-285

  Uckun, Fatih M ^a   Qazi, Sanjive ^a   Venkatachalam, Taracad ^a  

^a Paradigm Pharmaceuticals   (United States)

Author keywords

Anti HIV agents; CAS 258340 15 7; HI 443, in vitro anti HIV activity profile; Non nucleoside reverse transcriptase inhibitors; N 2 (2 thiophene)ethyl N 2 (5 bromopyridyl) thiourea

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HI 443; N' [2 (2 THIOPHENE)ETHYL] N' [2 (5 BROMOPYRIDYL)]THIOUREA; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE; THIOUREA; VIRUS ENVELOPE PROTEIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; VIROLOGY; VIRUS CULTURE;

ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; PLAQUE ASSAY; PYRIDINES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; THIOUREA; VIRAL ENVELOPE PROTEINS;

EID: 34147222637     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296619     Document Type: Article

References (38)

1. Gottlieb MS. AIDS - past and future. N Engl J Med. 2001 Jun 7;344(23):1788-1791.
2. Sepkowitz KA. AIDS - the first 20 years. N Engl J Med. 2001 Jun 7;344(23):1764-1772.
3. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001 Mar 15;344(11):824-831.
4. Richman DD. HIV chemotherapy. Nature. 2001 Apr 19;410(6831):995-1001.
5. Shafer RW, Vuitton DA. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother. 1999 Mar;53(2):73-86.
6. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. 1999 Dec 16;341(25):1874-1881.
7. Rey D, Schmitt MR Partisani M, Hess-Kempf G, Krantz V, de Mautort E, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):459-462.
8. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. Aids. 2000 Jan 28;14(2):163-171.
9. Johnson VA. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J Infect Dis. 1995 Mar;171 Suppl 2:S140-149.
10. Lin PF, Gonzalez CJ, Griffith B, Friedland G, Calvez V, Ferchal F, et al. Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir Ther. 1999;4(1):21-28.
11. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. Aids. 2000 Jan 28;14(2):F9-15.
12. Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1107-1115.
13. Suzuki K, Kaufmann GR, Mukaide M, Cunningham P, Harris C, Leas L, et al. Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1293-1296.
14. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis. 2001 Sep 15;184(6):781-784.
15. Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, et al. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):450-458.
16. Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, et al. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):377-380.
17. Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 1999 Dec;59(4):507-511.
18. Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, et al. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse- transcriptase inhibitors. Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):274-282.
19. Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J Infect Dis. 2000 Feb;181(2):491-497.
20. O'Brien WA. Resistance against reverse transcriptase inhibitors. Clin Infect Dis. 2000 Jun;30 Suppl 2:S185-192.
21. Pillay D, Taylor S, Richman DD. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol. 2000 Jul-Aug;10(4):231-253.
22. Briones C, Soriano V, Gonzalez-Lahoz J. Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. Aids. 2000 Jul 28;14(11):1659-1660.
23. Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):36-43.
24. Gutierrez F, Molto J, Escolano C, Mora A, Pasquau F, Gregori J, et al. [Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy]. Med Clin (Barc). 2000 Oct 7;115(11):401-404.
25. Palmer S, Shafer RW, Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. Aids. 1999 Apr 16;13(6):661-667.
26. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):266-273.
27. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. Aids. 2000 Jan 28;14(2):F17-23.
28. Uckun FM. Unmet challenges in HIV therapy and potential of stampidine. Arzneimittel-Forschung (Drug Research). 2006 Feb;56(2a):117-120.
29. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol. 2000 Nov 1;60(9):1251-1265.
30. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, et al. N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-3416.
31. Uckun FM, Venkatachalam TK, inventors; Thiophene-ethyl thiourea compounds and use. United States patent 6,124,324. 2000.
32. Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman D. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob Agents Chemother. 2002 Nov;46(11):3613-3616.
33. Richman DD, Johnson VA, Mayers DL. In vitro evaluation of experimental agents for anti-HIV activity. Current Protocols in Immunology. Brooklyn, NY: John Wiley & Sons, Inc. 1993:Unit 12.9, 1-21.
34. Uckun FM, Pendergrass S, Qazi S, Venkatachalam TK. In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates. Arzneimittel-Forschung (Drug Research). 2004;54(1):69-77.
35. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):157-162.
36. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol. 1997 Jul;71(7):5441-5448.
37. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Jr., Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1167-1173.
38. D'Cruz OJ, Samuel P, Uckun FM. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod. 2004 Dec;71(6):2037-2047.